Monopar Therapeutics (MNPR) Stock Forecast & Price Target

Monopar Therapeutics is viewed positively because ALXN1840 has built a compelling late-stage evidence base, with Phase 3 copper mobilization, neurological improvement, hepatic stabilization, and 645 patient-years of follow-up in 266 patients supporting a coherent benefit-risk story. The July initiation of the rolling NDA submission is a meaningful de-risking step, while Fast Track, Orphan Drug, and Rare Pediatric Disease designations add regulatory flexibility and the potential for non-dilutive value through a Priority Review Voucher. Financially, cash of $134.3M supports operations through at least YE27, and the radiopharmaceutical pipeline in MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac provides additional upside beyond Wilson disease.

Monopar Therapeutics is exposed to substantial clinical and regulatory uncertainty because ALXN1840 and its radiopharmaceutical pipeline remain investigational, and failure to show statistical, clinical, or safety benefit could delay or block approval from the FDA and other regulators. Commercially, the company faces a crowded Wilson disease landscape, potential clinician resistance to switching therapies, and reimbursement dependence that could prevent meaningful revenue generation even if a product is approved. Its negative outlook is further supported by financing risk, since continued development and eventual commercialization may require new partnerships or external capital, increasing dilution and execution pressure.